Lanreotide treatment of metastatic hepatocellular carcinoma resulting in partial regression and more than 3 years of progression-free survival.

Détails

ID Serval
serval:BIB_4D9AF9D2ABCC
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Titre
Lanreotide treatment of metastatic hepatocellular carcinoma resulting in partial regression and more than 3 years of progression-free survival.
Périodique
Acta Gastro-enterologica Belgica
Auteur(s)
Borbath I., Lhommel R., Guiot Y., Coche E., Sempoux C.
ISSN
0001-5644 (Print)
ISSN-L
0001-5644
Statut éditorial
Publié
Date de publication
2012
Peer-reviewed
Oui
Volume
75
Numéro
2
Pages
270-273
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article Publication Status: ppublish
Résumé
We describe the case of a 54 years old woman, with hepatitis B, in whom the diagnosis of a 6 cm hepatocellular carcinoma (HCC) in the left liver was made in 2001. Alpha-foeto-protein (AFP) was 63 ng/mL (NI < 10 ng/mL). After work-up including liver and tumor biopsy confirming HCC and only fibrosis in the nontumoral liver, left hepatectomy was performed. Final pathology showed a well differentiated HCC with tumoral portal vein thrombosis. Unfortunately, lung and mediastinal adenopathies were detected by CT scan 17 months later. Mediastinal nodes were punctured by endosonographic ultrasound, confirming HCC. The patient started treatment with Lanreotide 30 mg twice a month (Somatuline PR, Ipsen). Three months later, CT showed decrease in size of the mediastinal nodes and complete disappearance of the lung nodes. This objective response lasted for 42 months. The treatment was without any significant side effect. Retrospectively, immunohistochemistry was performed to detect somatostatine receptors (sstr) 2. Both the primary tumor and the node showed intense membranous and cytoplasmic staining for sstr2. In 2006, AFP rose and CT showed the appearance of a new mediastinal node. At that time, octreoscan was performed and showed uptake in the new node, although insufficient for metabolic radiotherapy. This case suggests that, although a number of randomized controlled trials did not show a benefit of somatostatin analogues in the treatment of advanced HCC, a subset of patients could benefit from treatment provided their tumor expresses sstr2, on which the existing drugs are efficient.
Mots-clé
Antineoplastic Agents/therapeutic use, Carcinoma, Hepatocellular/drug therapy, Carcinoma, Hepatocellular/secondary, Disease-Free Survival, Female, Humans, Liver Neoplasms/pathology, Liver Neoplasms/surgery, Lung Neoplasms/drug therapy, Lung Neoplasms/secondary, Lymph Nodes/pathology, Lymphatic Metastasis, Mediastinum, Middle Aged, Peptides, Cyclic/therapeutic use, Remission Induction, Somatostatin/analogs & derivatives, Somatostatin/therapeutic use
Pubmed
Web of science
Création de la notice
19/01/2015 11:13
Dernière modification de la notice
20/08/2019 14:02
Données d'usage